STEPS for cost-effective prescribing of serotonin-norepinephrine reuptake inhibitors (SNRIs) in major depressive disorder: Focus on venlafaxine (Effexor®) versus duloxetine (Cymbalta®)

Mental Health Clinician

Volumn 3, Issue 4, 2013, Pages 205-210

  Alipour, Azita ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

antidepressant; major depressive disorder; serotonin norepinephrine reuptake inhibitor (SNRI)

Indexed keywords

EID: 84904471406     PISSN: None     EISSN: 21689709     Source Type: Journal    
DOI: 10.9740/mhc.n172840     Document Type: Article

References (40)

1. Pratt LA, Brody DJ, Gu Q. Antidepressant use in persons aged 12 and over: United States 2005-2008. NCHS Data Brief, October 2011.
2. Benedict A, Arellano J, De Cock E, Baird J. Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland. J Affect Disord. 2010;120(1-3):94-104. DOI: 10.1016/j.jad.2009.04.017. PubMed PMID: 19497623.
3. Forest Laboratories Inc [Internet]. New York: Forest Laboratories. Forest Laboratories Submits New Drug Application for Levomilnacipran for the Treatment of Major Depressive Disorder September 2012; [about 3 screens]. Available from: http://frx.investorhq.businesswire.com/pressrelease/business-development-news/forest-laboratories-submits-newdrug-application-levomilnacipran.
4. American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. Arlington (VA): American Psychiatric Association (APA); 2010 Oct. 152 p.
5. Drugs.com [Internet]. Virginia: Drug Information Online; c2000-13. US Pharmaceutical Sales - Q2 2013; Updated: 2013 August; [about 4 screens]. Available from: http://www.drugs.com/stats/top100/units.
6. Thomson Reuters Micromedex Clinical Evidence Solutions [Internet]. Thomson Reuters; c2013 [cited 2013 Aug 10].
7. Cobb C, Crichlow R. Duloxetine (Cymbalta) for treatment of major depressive disorder. Am Fam Physician. 2005;72(6):1099-101.
8. Hawton K, Bergen H, Simkin S, Cooper J, Waters K, Gunnell D, et al. Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. Br J Psychiatry. 2010;196(5):354-8. DOI: 10.1192/bjp.bp.109.070219. PubMed PMID: 20435959; PubMed Central PMCID: PMC2862059.
9. Clinical Handbook of Psychotropic Drugs. 19th ed. Hogrefe Publishing 2012.
10. Bosse GM, Spiller HA, Collins AM. A fatal case of venlafaxine overdose. J Med Toxicol. 2008;4(1):18- 20. DOI: 10.1007/BF03160945.
11. Cymbalta [package insert]. Indianapolis, IN: Eli-Lilly and Company; 2012.
12. Levine M, Truitt CA, O'Connor AD. Cardiotoxicity and serotonin syndrome complicating a milnacipran overdose. J Med Toxicol. 2011;7(4):312-6. DOI: 10.1007/s13181-011-0167-1. PubMed PMID: 21735310; PubMed Central PMCID: PMC3550178.
13. Savella [package insert]. St. Louis, MO: Forest Pharmaceuticals Inc; 2009.
14. Fetzima [package insert]. St. Louis, MO: Forest Laboratories Inc; 2013.
15. Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ. 2013;346:f288. DOI: 10.1136/bmj.f288. PubMed PMID: 23360890; PubMed Central PMCID: PMC3558546.
16. Azcert.Org [Internet]. Arizona: Credible Meds; 2013; [about 1 screen]. Available from: www.azcert.org/drugs_to_avoid.pdf.
17. Howell C, Wilson AD, Waring WS. Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. Br J Clin Pharmacol. 2007;64(2):192-7. DOI: 10.1111/j.1365-2125.2007.02849.x. PubMed PMID: 17298480; PubMed Central PMCID: PMC2000637.
18. Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arztebl Int. 2011; 108(41):687-93.
19. Pristiq [package insert]. Philadelphia, PA: Pfizer Inc; 2013.
20. Norman TR, Olver JS. Duloxetine in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat. 2008;4(6):1169-80.
21. Eli Lilly and Company [Internet]. Indiana: Lilly Research Laboratories; 2005 Oct 5; [about 2 screens]. Available from: www.fda.gov/downloads/Safety/MedWatch/.../UCM164428.pdf.
22. The Maudsley Prescribing Guidelines. 10th ed. Boca Raton, LF: Taylor & Francis; 2009.
23. Montgomery SA. Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants. CNS Spectr. 2008;13(7 Suppl 11):27-33.
24. Tierney JG. Treatment-resistant depression: managed care considerations. J Manag Care Pharm. 2007;13(6 Suppl A):S2-7. PubMed PMID: 17672818.
25. Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, et al. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J Psychiatr Res. 2008;42(1):22-34. DOI: 10.1016/j.jpsychires.2007.01.008. PubMed PMID: 17445831.
26. Olié JP, Gourion D, Montagne A, Rostin M, Poirier MF. Milnacipran and venlafaxine at flexible doses (up to 200 mg/day) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-Week randomized, double-blind exploratory study. Neuropsychiatr Dis Treat. 2010;6:71-9.
27. Medscape Pharmacists [Internet]. New York: Medscape; cF0750422013. Levomilnacipran: A Brief Overview; 2013 July 26; [About 2 screens]. Available From: http://www.medscape.com/viewarticle/808378.
28. Auclair AL, Martel JC, Assié MB, Bardin L, Heusler P, Cussac D, et al.. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology. 2013;70:338-47. DOI: 10.1016/j.neuropharm.2013.02.024. PubMed PMID: 23499664.
29. Cipriani A, Koesters M, Furukawa TA, Nosè M, Purgato M, Omori IM, et al. Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev. 2012;10:CD006533. DOI: 10.1002/14651858.CD006533.pub2. PubMed PMID: 23076926.
30. Mohr P, Bitter I, Svestka J, Seifritz E, Karamustafalioglu O, Koponen H, et al. Management of depression in the presence of pain symptoms. Psychiatr Danub. 2010; 22(1):4-13.
31. Goldenberg DL. Initial treatment of fibromyalgia in adults. In: UpToDate, Schur, PH (Ed), UpToDate, Waltham, MA, 2013.
32. Dwight MM, Arnold LM, O'Brien H, Metzger R, Morris-Park E, Keck PE Jr. An open clinical trial of venlafaxine treatment of fibromyalgia. psychosomatics. 1998;39(1):14-7. DOI: 10.1016/S0033-3182(98)71375-1.
33. Sayar K, Aksu G, Ak I, Tosun M. Venlafaxine treatment of fibromyalgia. Ann Pharmacother. 2003;37(11):1561-5. DOI: 10.1345/aph.1D112. PubMed PMID: 14565792.
34. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;(4):CD005454. DOI: 10.1002/14651858.CD005454.pub2. PubMed PMID: 17943857.
35. Lindsay TJ, Rodgers BC, Savath V, Hettinger K. Treating diabetic peripheral neuropathic pain. Am Fam Physician 2010;82(2):151-8.
36. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain. 2004;110(3):697-706.
37. Dunn JD, Cannon E, Mitchell MP, Curtiss FR. Utilization and drug cost outcomes of a step-therapy edit for generic antidepressants in an HMO in an integrated health system. J Manag Care Pharm. 2006;12(4):294-302.
38. van Baardewijk M, Vis PM, Einarson TR. Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder. Curr Med Res Opin. 2005;21(8):1271-9.
39. Khan AY, Macaluso M. Duloxetine for the treatment of generalized anxiety disorder: a review. Neuropsychiatr Dis Treat. 2009;5:23-31. PubMed PMID: 19557096.
40. Wise TN, Wiltse CG, Iosifescu DV, Sheridan M, Xu JY, Raskin J. The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity. Int J Clin Pract. 2007;61(8):1283-93. DOI: 10.1111/j.1742-1241.2007.01476.x. PubMed PMID: 17590215; PubMed Central PMCID: PMC2408656.